NCT05300269View on ClinicalTrials.gov

SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

October 31, 2026

Conditions
Locally Advanced Rectal Cancer
Interventions
DRUG

SHR-1701；Capecitabine；Oxaliplatin

"Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m\^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m\^2, day1, iv, q3w"

Trial Locations (1)

200032

RECRUITING

Fudan University Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY